Literature DB >> 10493822

Kinetic and structural characteristics of the inhibition of enoyl (acyl carrier protein) reductase by triclosan.

W H Ward1, G A Holdgate, S Rowsell, E G McLean, R A Pauptit, E Clayton, W W Nichols, J G Colls, C A Minshull, D A Jude, A Mistry, D Timms, R Camble, N J Hales, C J Britton, I W Taylor.   

Abstract

Triclosan is used widely as an antibacterial agent in dermatological products, mouthwashes, and toothpastes. Recent studies imply that antibacterial activity results from binding to enoyl (acyl carrier protein) reductase (EACPR, EC 1.3.1.9). We first recognized the ability of triclosan to inhibit EACPR from Escherichia coli in a high throughput screen where the enzyme and test compound were preincubated with NAD(+), which is a product of the reaction. The concentration of triclosan required for 50% inhibition approximates to 50% of the enzyme concentration, indicating that the free compound is depleted by binding to EACPR. With no preincubation or added NAD(+), the degree of inhibition by 150 nM triclosan increases gradually over several minutes. The onset of inhibition is more rapid when NAD(+) is added. Gel filtration and mass spectrometry show that inhibition by triclosan is reversible. Steady-state assays were designed to avoid depletion of free inhibitor and changes in the degree of inhibition. The results suggest that triclosan binds to E-NAD(+) complex, with a dissociation constant around 20-40 pM. Triclosan follows competitive kinetics with respect to NADH, giving an inhibition constant of 38 pM at zero NADH and saturating NAD(+). Uncompetitive kinetics are observed when NAD(+) is varied, giving an inhibition constant of 22 pM at saturating NAD(+). By following regain of catalytic activity after dilution of EACPR that had been preincubated with triclosan and NAD(+), the rate constant for dissociation of the inhibitor (k(off)) is measured as 1.9 x 10(-4) s(-1). The association rate constant (k(on)) is estimated as 2.6 x 10(7) s(-1) M(-1) by monitoring the onset of inhibition during assays started by addition of EACPR. As expected, the ratio k(off)/k(on) = 7.1 pM is similar to the inhibition constants from the steady-state studies. The crystal structure of E. coli EACPR in a complex with coenzyme and triclosan has been determined at 1.9 A resolution, showing that this compound binds in a similar site to the diazaborine inhibitors. The high affinity of triclosan appears to be due to structural similarity to a tightly bound intermediate in catalysis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10493822     DOI: 10.1021/bi9907779

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  58 in total

Review 1.  Fatty acid biosynthesis revisited: structure elucidation and metabolic engineering.

Authors:  Joris Beld; D John Lee; Michael D Burkart
Journal:  Mol Biosyst       Date:  2014-10-31

Review 2.  Potential impact of increased use of biocides in consumer products on prevalence of antibiotic resistance.

Authors:  Peter Gilbert; Andrew J McBain
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

Review 3.  Targeting InhA, the FASII enoyl-ACP reductase: SAR studies on novel inhibitor scaffolds.

Authors:  Pan Pan; Peter J Tonge
Journal:  Curr Top Med Chem       Date:  2012       Impact factor: 3.295

4.  Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI).

Authors:  Jiangwei Yao; John B Maxwell; Charles O Rock
Journal:  J Biol Chem       Date:  2013-11-04       Impact factor: 5.157

5.  Antimicrobial activity Study of triclosan-loaded WBPU on Proteus mirabilis in vitro.

Authors:  Ye Tian; Zhongyu Jian; Jianzhong Wang; Wei He; Qinyu Liu; Kunjie Wang; Hong Li; Hong Tan
Journal:  Int Urol Nephrol       Date:  2017-02-01       Impact factor: 2.370

6.  Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK).

Authors:  Hedia Marrakchi; Walter E Dewolf; Chad Quinn; Joshua West; Brian J Polizzi; Chi Y So; David J Holmes; Shannon L Reed; Richard J Heath; David J Payne; Charles O Rock; Nicola G Wallis
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

7.  Slow-tight-binding inhibition of enoyl-acyl carrier protein reductase from Plasmodium falciparum by triclosan.

Authors:  Mili Kapoor; C Chandramouli Reddy; M V Krishnasastry; Namita Surolia; Avadhesha Surolia
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

8.  Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.

Authors:  Gang Cheng; Stephen P Muench; Ying Zhou; Gustavo A Afanador; Ernest J Mui; Alina Fomovska; Bo Shiun Lai; Sean T Prigge; Stuart Woods; Craig W Roberts; Mark R Hickman; Patty J Lee; Susan E Leed; Jennifer M Auschwitz; David W Rice; Rima McLeod
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

9.  Mechanism and inhibition of the FabV enoyl-ACP reductase from Burkholderia mallei.

Authors:  Hao Lu; Peter J Tonge
Journal:  Biochemistry       Date:  2010-02-16       Impact factor: 3.162

10.  Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.

Authors:  Gustavo A Afanador; Stephen P Muench; Martin McPhillie; Alina Fomovska; Arne Schön; Ying Zhou; Gang Cheng; Jozef Stec; Joel S Freundlich; Hong-Ming Shieh; John W Anderson; David P Jacobus; David A Fidock; Alan P Kozikowski; Colin W Fishwick; David W Rice; Ernesto Freire; Rima McLeod; Sean T Prigge
Journal:  Biochemistry       Date:  2013-12-13       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.